Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions

Axsome Therapeutics (NasdaqGM:AXSM) received U.S. FDA approval for AUVELITY for agitation associated with dementia due to Alzheimer’s disease. AUVELITY becomes the first approved treatment in this indication, addressing a major unmet medical need. The decision introduces a new commercial opportunity for Axsome in neuropsychiatric disorders. Axsome’s AUVELITY approval comes with the stock at $216.47 and follows very large 3 year and 5 year share price gains, alongside a 96.5% return over the past year. The shares are up 21.5% over the past month and 21.1% year to date, while the stock is down 3.2% over the past week. For investors tracking NasdaqGM:AXSM, this new indication expands the company’s presence in central nervous system conditions and adds a differentiated product to its portfolio. The approval may affect how the market views Axsome’s positioning in neuropsychiatric treatments and its ability to pursue additional indications over time. Stay updated on the most important news stories for Axsome Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Axsome Therapeutics. NasdaqGM:AXSM Earnings & Revenue Growth as at May 2026 📰 Beyond the headline: 0 risks and 3 things going right for Axsome Therapeutics that every investor should see. Quick Assessment ✅ Price vs Analyst Target: At US$216.47, the stock trades about 20% below the US$270.28 consensus target, with a range of US$200 to US$328.81. ✅ Simply Wall St Valuation: Shares are described as trading 72.8% below an estimated fair value, flagging a valuation upside according to that model. ✅ Recent Momentum: A 21.5% gain over the last 30 days shows strong short term momentum around this FDA decision. To assess whether it is the right time to buy, sell or hold Axsome Therapeutics, you can review Simply Wall St's company report for the latest analysis of Axsome Therapeutics's Fair Value. Key Considerations 📊 The AUVELITY approval opens a new indication in Alzheimer’s related agitation, which could influence expectations around Axsome’s revenue mix in central nervous system disorders. 📊 Investors may want to watch prescription uptake for this new use, any updates to analyst price targets, and how the P/E of 59.2 compares with the Pharmaceuticals industry average of about 15.5. ⚠️ Despite zero flagged risks in the current dataset, investors may still want to track future safety communications or label changes related to AUVELITY. Dig Deeper For the full picture including more risks and rewards, check out the complete Axsome Therapeutics analysis. Alternatively, you can visit the community page for Axsome Therapeutics to see how other investors believe this latest news will impact the company's narrative. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free